Meeting
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
Authors
Hui-Li Wong
Department of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada
Hui-Li Wong , Ying Wang , Yaling Yin , Hagen F. Kennecke , Winson Y. Cheung , Daniel John Renouf , Sharlene Gill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 468)
DOI
10.1200/JCO.2017.35.4_suppl.468
Abstract #
468
Poster Bd #
M8
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Gang Jin
Poster
2021 Gastrointestinal Cancers Symposium
Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.
First Author: Julien Taieb
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2019 Gastrointestinal Cancers Symposium
Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).
First Author: Markus Kieler